LSL Pharma Group Completes Acquisition of Laboratoire Du-Var Inc.
LSL PHARMA GROUP INC. (TSXV: LSL), an integrated Canadian pharmaceutical company, is excited to share the completion of its acquisition of Laboratoire Du-Var Inc., a notable player in the cosmetics and natural health products sector since 1947. This acquisition not only marks a significant step for LSL Pharma but also boosts its production capacity for liquid and semi-solid products, enhancing its manufacturing capabilities remarkably.
Strategic Benefits of the Acquisition
With the integration of Du-Var into LSL Pharma's operations, the company doubles its production capacity and diversifies its manufacturing infrastructure. This pivotal move is expected to broaden LSL Pharma's customer base significantly within the Contract Manufacturing Organization (CMO) space. Additionally, it opens doors to emerging markets in natural health products, cosmetics, and personal care, positioning LSL Pharma as a leader in these sectors.
Leadership Insights
François Roberge, President and CEO of LSL Pharma, expressed his enthusiasm regarding the acquisition, stating, "This milestone is not just about increasing our production capacity, but also about diversifying our product offerings and attracting new customers that align with our core business. We're thrilled to welcome the highly regarded Du-Var team into our fold." This acquisition allows LSL Pharma to enhance its footprint in an industry that is continuously evolving based on consumer trends.
Transaction Overview
The acquisition terms include the renewal of Du-Var's operational line of credit and other related liabilities, amounting to a total of $3.2 million. In the fiscal year ending August 31, 2025, Du-Var reported an Adjusted EBITDA of $0.5 million, generated from $4.4 million in revenues. Du-Var’s assets at that time were valued at $6.9 million, while liabilities were recorded at $5.1 million. This addition also includes 30,000 square feet of production space and advanced manufacturing equipment, which is poised to increase LSL Pharma’s revenues in its CMO segment significantly.
About Laboratoire Du-Var Inc.
Founded in the heart of the cosmetic industry in 1947, Laboratoire Du-Var has established itself as a pioneer in developing high-quality cosmetics and health-focused products. The company’s commitment to quality and expertise has created a diverse clientele both domestically and internationally. With certifications including cGMP and recognition from major health authorities, Du-Var is well-positioned to contribute to LSL Pharma’s mission.
About LSL Pharma Group Inc.
As a leading integrated Canadian pharmaceutical organization, LSL Pharma specializes in manufacturing and commercializing a wide range of high-quality products, including sterile ophthalmic medications. The company's operations focus on delivering innovative solutions combined with top standards in quality, making it a prominent name in both the pharmaceutical and cosmetic sectors. The group includes various subsidiaries focused on excellence and consumer health.
Frequently Asked Questions
What recent milestone did LSL Pharma Group achieve?
LSL Pharma Group completed the acquisition of Laboratoire Du-Var Inc., enhancing its production capabilities.
How does this acquisition benefit LSL Pharma Group?
This acquisition allows LSL Pharma to double its production capacity, diversify its offerings, and reach new customer segments.
Who is the President and CEO of LSL Pharma?
François Roberge serves as the President and CEO of LSL Pharma Group.
What was Du-Var's financial performance prior to the acquisition?
In the 12 months ending in August 2025, Du-Var reported Adjusted EBITDA of $0.5 million and revenues of $4.4 million.
What types of products does Laboratoire Du-Var specialize in?
Laboratoire Du-Var specializes in developing cosmetics, natural health products, and personal care products, along with pet care items.
